Fig. 5

Intra-thalamic injection of YC-1 or MCC950 suppressed ITC-induced activation of microglia and astrocytes in peri-thalamic lesion sites. A Representative immunofluorescence images showing the expressions of GFAP and Iba-1 in the peri-thalamic lesion sites. Scale bar = 100 μm. B Quantification of cell number showed YC-1 or MCC950 decreased Iba-1 positive cells in the peri-thalamic lesion sites in ITC rats (n = 5, F_2,12 = 56.07, ^###p < 0.001 vs ITC + Veh). C Quantification of cell number showed YC-1 or MCC950 decreased GFAP-positive cells in the peri-thalamic lesion sites in ITC rats (n = 5, F_2,12 = 44.62, ^###p < 0.001 vs ITC + Veh). D Representative magnified images of microglia (top) and the corresponding black-and-white, skeletonized images (bottom) in the peri-thalamic lesion sites. Scale bar = 25 μm. E Quantification of process length showed YC-1 or MCC950 increased the process length of microglia in the peri-thalamic lesion sites (n = 5, F_2,12 = 44.37, ^###p < 0.001 vs ITC + Veh). F Quantification of endpoint showed YC-1 or MCC950 increased the endpoints in microglia in the peri-thalamic lesion sites (n = 5, F_2,12 = 22.58, ^##p < 0.01, ^###p < 0.001 vs ITC + Veh). G Representative western blots of Iba-1 and GFAP expression in total proteins of the peri-thalamic lesion sites in ITC rats. H Quantitative summary result showed YC-1 or MCC950 decreased Iba-1 expression in the peri-thalamic lesion sites in ITC rats (n = 5, F_2,12 = 16.17, ^###p < 0.01 vs ITC + Veh). I Quantitative summary result showed YC-1 or MCC950 decreased GFAP expression in the peri-thalamic lesion sites in ITC rats (n = 5, F_2,12 = 37.29, ^###p < 0.001 vs ITC + Veh). Data are expressed as mean ± SEM, one-way ANOVA followed by the Tukey test